Everything below concerns peptide backbone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
== See also == Cantonese salted fish Cured fish Salted squid Dried and salted cod Brining Gibbing Pickling salt Spekesild (cured, salted Atlantic herring) Surströmming (lightly-salted soured Baltic herring)
Derivatization is a technique used in chemistry which converts a chemical compound into a product (the reaction's derivate) of similar chemical structure, called a derivative. Generally, a specific functional group of the compound participates in the derivatization reaction and transforms the educt to a derivate of deviating reactivity, solubility, boiling point, melting point, aggregate state, or chemical composition. Resulting new chemical properties can be used for quantification or separation of the educt. Derivatization techniques are frequently employed in chemical analysis of mixtures and in surface analysis, e.g. in X-ray photoelectron spectroscopy where newly incorporated atoms label characteristic groups.
== Bibliography == Denise Y. Arnold, Christine A. Hastorf (2008). Heads of State: Icons, Power, and Politics in The Ancient and Modern Andes. Left Coast Press. ISBN 9781598741711. Terence N. D'Altroy (1992). Provincial Power in The Inca Empire. Smithsonian Institution Press. ISBN 9781560981152. Terence N. D'Altroy (2003). The Incas. Wiley-Blackwell. ISBN 1-4051-1676-5. Teofilo Laime Ajacopa (2007), Diccionario Bilingue Iskay Simipi Yuyayk'ancha, La Paz. (Quechua-Spanish Dictionary) Terry V. LeVine, Ed. (1992), Inca Storage Systems, University of Oklahoma Press, ISBN 0-8061-2440-7. Timothy Parsons (2010). The Rule of Empires: Those Who Built Them, Those Who Endured Them, and Why They Always Fall. Oxford University Press. ISBN 9780199746194
A level of <70 mg/dL (<3.8 mmol/L) is described as a hypoglycemic attack (low blood sugar). Most diabetics know when they are hypoglycemic and seek food or a sweet drink to raise their glucose levels. Intensive efforts to achieve blood sugar levels close to normal have been shown to triple the risk of the most severe form of hypoglycemia, in which the person requires assistance from by-standers in order to treat the episode. Among intensively controlled type 1 diabetics, 55% of episodes of severe hypoglycemia occur during sleep, and 6% of all deaths in diabetics under the age of 40 are from hypoglycemia at night. Hypoglycemia can be problematic if it occurs while driving as it can affect a person's thinking process, coordination, and state of consciousness. Some people are more prone to hypoglycemia as they have reported fewer warning symptoms, and their body released less epinephrine (a hormone that helps raise blood glucose). Additionally, individuals with a history of hypoglycemia-related driving mishaps appear to use sugar at a faster rate. Drivers with diabetes susceptible to driving mishaps should monitor their blood sugar to be not less than 70 mg/dL (3.9 mmol/L). Instead, these drivers are advised to treat hypoglycemia and delay driving until their blood glucose is above 90 mg/dL (5 mmol/L).
Sources: en.wikipedia.org
The reduction of the permissible exposure limit (PEL) for respirable crystalline silica from 250 to 50 micrograms per cubic meter of air, averaged over an 8-hour shift. Shifts the focus of controlling silica exposure from the use of PPE (respirators) to the use of engineering controls (such as using water-integrated tools or vacuum systems) and administrative controls (limiting exposure time per shift). Employers are still required to provide respirators when engineering and administrative controls cannot adequately limit exposure. Additional provisions include limiting worker access to high exposure areas, signage requirements in high exposure areas, the development of a written exposure control plan, and training for workers on silica risks and how to limit exposures. Special equipment may be needed to prevent machine water from evaporating and leaving behind dust, and the standard also provides requirements for cleaning up the slurry left behind when water-integrated tools are used as an engineering control. Requires medical exams for highly exposed workers which include a discussion with a physician or licensed health care provider (PLHCP) of prior respiratory health, chest X-ray, pulmonary function test, latent tuberculosis infection, and any other tests deemed necessary by the PLHCP, which are to occur within 30 days of initial silica exposure and must be made available for renewal at least every three years unless the PLHCP deems otherwise.
Globally there are about 114 million and 20 million cases of hepatitis A and hepatitis E respectively, but these generally resolve and do not become chronic. Hepatitis D virus is a "satellite" of hepatitis B virus (it can only infect in the presence of hepatitis B), and co-infects nearly 20 million people with hepatitis B, globally. Hepatic encephalopathy is caused by an accumulation of toxins in the bloodstream that are normally removed by the liver. This condition can result in coma or death if not treated. Budd–Chiari syndrome is a condition caused by blockage of the hepatic veins (including thrombosis) that drain the liver. It presents with the classical triad of abdominal pain, ascites and liver enlargement. Many diseases of the liver are accompanied by jaundice caused by increased levels of bilirubin in the system. The bilirubin results from the breakup of the hemoglobin of dead red blood cells; normally, the liver removes bilirubin from the blood and excretes it through bile. Other disorders caused by excessive alcohol consumption are grouped under alcoholic liver diseases and these include alcoholic hepatitis, fatty liver, and cirrhosis. Factors contributing to the development of alcoholic liver diseases are not only the quantity and frequency of alcohol consumption, but can also include gender, genetics, and liver insult. Liver damage can also be caused by drugs, particularly paracetamol and drugs used to treat cancer. A rupture of the liver can be caused by a liver shot used in combat sports. Primary biliary cholangitis is an autoimmune disease of the liver.
=== Gambling === To help pay for his 2019 capital spending bill, Pritzker expanded gambling, allowing more casinos and legalized sports betting. This did not mean new casinos could be built and sports betting could begin right away: granting licenses for such activities is the job of the Illinois Gaming Board, and the process is a complex one, lasting several months or more and involving extensive criminal background checks, among other requirements. According to the governor's office, gambling will bring an additional $350 million in revenue each year. This gambling expansion bill extends to Chicago, something the city wanted. Chicago mayor Lori Lightfoot emphasized economic development in the city's South and West sides during her campaign. She has argued that a new casino, privately owned, and associated hospitality and entertainment venues will bring money into the city. On May 5, 2022, Lightfoot announced that she had selected Bally's Corporation's bid to construct a casino resort near the Chicago River.
A Mesmerian Experiment (French: Le Baquet de Mesmer) is a 1905 French silent trick film by Georges Méliès. It was sold by Méliès's Star Film Company and is numbered 693–695 in its catalogues. Méliès appears in the film Doctor Mesmer. The film has few illusions, and is mainly a vehicle for its troupe of dancers, identified in Méliès's American film catalogue as the "Snow-drops" of London's Alhambra Theatre of Variety. The film's technical effects were carried out with pyrotechnics and substitution splices.
On 3 December 2004, the twentieth anniversary of the disaster, a man falsely claiming to be a Dow representative named Jude Finisterra was interviewed on BBC World News. He claimed that the company had agreed to clean up the site and compensate those harmed in the accident, by liquidating Union Carbide for US$12 billion. Dow quickly issued a statement saying that they had no employee by that name—that he was an impostor, not affiliated with Dow, and that his claims were a hoax. The BBC later broadcast a correction and an apology. Jude Finisterra was actually Andy Bichlbaum, a member of the activist prankster group The Yes Men. In 2002, The Yes Men issued a fake press release explaining why Dow refused to take responsibility for the disaster and started up a website, at "DowEthics.com", designed to look like the real Dow website, but containing false information.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.